source
- Sanofi halts Nurix STAT6 degrader program two months after phase-1 startSanofi announced it is ending its collaboration with Nurix on a STAT6 degrader, just two months after the drug entered a phase-1 study. The two companies have worked together since 2019, with Sano…
- Biotech startups opt out of AI for drug discovery, say STATThe latest STAT AI Prognosis newsletter notes that a number of biotech startups are deliberately avoiding artificial intelligence in their drug discovery programs. These companies argue that AI ma…